Medline Expands Respiratory Solutions Portfolio to Improve Patient Outcomes

Medline partners with Smiths Medical to bring Portex® acapella® choice, a therapy device for patients with chronic pulmonary lung disease (COPD), to the post-acute market.

By Medline Newsroom Staff | September 11, 2019

Medline has entered an exclusive agreement with Smiths Medical to distribute Portex® acapella® choice, an oscillating positive expiratory pressure (OPEP) therapy device, to the post-acute channel. The addition aligns with Medline’s ongoing strategy to bring more clinically sophisticated solutions to market as part of its growing respiratory portfolio.

The acapella® choice device helps patients with chronic pulmonary lung disease (COPD) mobilize secretions and open airways. COPD patients include those with a range of progressive lung diseases, like patients with emphysema and chronic bronchitis.

In 2014, COPD ranked as the third leading cause of death in the U.S., and flare ups of COPD are common drivers for readmissions to care facilities. PEP therapy has been clinically proven to reduce hospital length of stay, which may help reduce the effects of re-admissions.

This new partnership is the latest step in the Medline respiratory solutions evolution.

“Our customers are caring for higher acuity patients and facing more and more clinical and financial demands in healthcare today. By shifting our focus to ensure new offerings support best practices and improved outcomes, we are well positioned to serve the needs across the continuum of care,” said Tim Finnigan, respiratory division president, Medline.

Just like healthcare facilities across the country, Medline and its teams keep patients at the center of what they do. The company’s respiratory solutions area alone launched 25 new products in the past two years by extending existing product lines, entering new partnerships or from manufacturing entirely new ones. Additionally, its team of clinical specialists has grown to more than a dozen, including four certified respiratory therapists who often travel onsite to answer questions.

“Medline is the only company in the respiratory space that truly offers a broad line of products in acute, in home care, in LTAC and all other points in the continuum of care. This level of product depth and clinical expertise is critical to being an integrated partner of choice,” Finnigan said.

Learn more about the benefits of acapella® choice here.

Share

Medline Newsroom Staff

Medline Newsroom Staff

Medline's newsroom staff researches and reports on the latest news and trends in healthcare.

View All Stories From This Author